Read on Twitter
Starting a thread of my clinical papers, similar to my previous threads of global oncology and cancer policy papers. Actually, my first peer reviewed paper was a clinical paper: a review on managing opioid induced constipation. 2015. https://www.tandfonline.com/doi/full/10.3109/00365521.2015.1054423
We then published a case report of using pazopanib for orbital granular cell tumor https://www.spandidos-publications.com/10.3892/ol.2015.3263
While I was in Japan, I also did some work on #sarcopenia in cancer patients. Not very high quality stuff, but I was taking baby steps in clinical research. https://www.spandidos-publications.com/10.3892/mco.2016.1015
Another work on #sarcopenia investigating its prognostic role on patients with metastatic gastric cancer. https://www.spandidos-publications.com/10.3892/or.2015.4475
We routinely prescribe prophylactic laxatives while starting patients on opioids. But should we also routinely prescribe antiemetics? We did a survey of Japanese physicians. https://www.liebertpub.com/doi/10.1089/jpm.2015.0203 cc @DeiselKain
Based on the results of this survey, we launched a double blind, placebo controlled RCT of prophylactic prochlorperazine for opioid induced N&V. https://theoncologist.onlinelibrary.wiley.com/doi/full/10.1634/theoncologist.2017-0225 #supportivecare
In 2016 in @CHematology , we reviewed the evidence for intermittent versus continuous docetaxel in mCRPC. #ProstateCancer https://www.sciencedirect.com/science/article/abs/pii/S1040842816300919
We also reviewed the evidence for treatment of locally advanced head and neck cancer. https://www.cancertreatmentreviews.com/article/S0305-7372(16)00010-4/abstract @KAZ99081
A #jugaad way to give antifungal prophylaxis when liposomal Amphotericin is unaffordable, les by @Poudyalbishesh . https://www.tandfonline.com/doi/abs/10.3109/10428194.2015.1055485?journalCode=ilal20
With @Poudyalbishesh , we also reported a case report of pure red cell aplasia with both imatinib and nilotinib. https://esmoopen.bmj.com/content/1/3/e000058
This was a report of outcomes of using donated clotting factors for surgeries in patients with hemophilia. https://onlinelibrary.wiley.com/doi/abs/10.1111/hae.13017
In this work led by @Poudyalbishesh again, we explored the safety and efficacy of azathioprine as 2L treatment for primary ITP. http://jnma.com.np/jnma/index.php/jnma/article/view/2832
In this @ASCO_pubs paper, we comprehensively review all available cheaper options for preventing chemo induced nausea and vomiting. https://ascopubs.org/doi/10.1200/JGO.2015.002477
After 2016 ASCO, we were kinda little excited about adoptive cell therapy 
https://ecancer.org/en/journal/editorial/59-adoptive-cell-therapy-and-modulation-of-the-tumour-microenvironment-new-insights-from-asco-2016 @ecancer
https://ecancer.org/en/journal/editorial/59-adoptive-cell-therapy-and-modulation-of-the-tumour-microenvironment-new-insights-from-asco-2016 @ecancer
Moving on to 2017, in this article, we discuss the issues and challenges with incorporating Bevacizumab to the treatment of advanced cervical cancer. https://ascopubs.org/doi/full/10.1200/JGO.2016.004895
In this meta-analysis @Annals_Oncology , we find that sorafenib significantly increases the risk of both serious and fatal adverse events. https://www.annalsofoncology.org/article/S0923-7534(19)32198-2/abstract
And once upon a time, we compared outcomes of haplo vs allo transplant https://www.futuremedicine.com/doi/10.2217/fon-2016-0443
https://www.futuremedicine.com/doi/10.2217/fon-2016-0443
In another paper @Annals_Oncology , we pooled the results from ASSURE and S-TRAC. I hope nobody is using adjuvant sunitinib in RCC anymore. @Ron_cology https://www.annalsofoncology.org/article/S0923-7534(19)32047-2/fulltext
During oncology training, we learn this like a mantra: squamous NSCLC cis-gem but nonsquamous NSCLC cis-peme. How strong do you think is the evidence behind this? I learned a lot working on this @JAMAOnc paper with @VPrasadMDMPH https://jamanetwork.com/journals/jamaoncology/fullarticle/2645853
And if you use regorafenib in #HCC, you should read this paper in @NatRevClinOncol with @VPrasadMDMPH : https://www.nature.com/articles/nrclinonc.2017.100
And if you use olaparib in breast cancer, please read this paper in @ecancer : https://ecancer.org/en/journal/editorial/75-the-olympiad-trial-who-won-the-gold
Moving from choosing wisely to #avoidingwisely, here’s a list of low value interventions to avoid in oncology practice: https://ecancer.org/en/journal/article/727-low-value-practices-in-oncology-contributing-to-financial-toxicity
Primary prophylaxis for Febrile Neutropenia for patients receiving FEC-Docetaxel chemo for breast cancer. What’s the best approach? https://ascopubs.org/doi/full/10.1200/JGO.2016.008540
Also, @sarojniraula and I conducted a trial level meta analysis to test whether a shorter course of adjuvant trastuzuamb was non inferior to 1 year for HER2 positive breast cancer. The results were not what we had hoped for. https://www.cancertreatmentreviews.com/article/S0305-7372(17)30124-X/abstract
Later, we updated the meta-analysis with new trial data but the conclusions remained unchanged. https://link.springer.com/article/10.1007/s10549-018-4967-8 @sarojniraula
In this work led by @bhemato , we revisited the role of autologous transplant for MM in the era of novel agents induction. https://jamanetwork.com/journals/jamaoncology/fullarticle/2667738
One of those works that I’m quite proud of having written. Why do we keep treating patients with cancer until the very end of life? With @sarojniraula : https://ecancer.org/en/journal/article/826-cancer-treatment-in-the-last-6-months-of-life-when-inaction-can-outperform-action
Does H Pylori eradication therapy to prevent gastric cancer increase all cause mortality? Our meta-analysis in @IntJCanc : https://onlinelibrary.wiley.com/doi/10.1002/ijc.31772
Are you confused as to why some adjuvant immunotherapy trials run for 1 year and why some 2 or 3? Then this paper with @drdgoldstein is for you. https://link.springer.com/article/10.1007/s12032-018-1218-0
The title says it all. Learned a lot from @JackWestMD by working on this piece. https://jamanetwork.com/journals/jamaoncology/fullarticle/2705603
Moving on to 2019, using the IPD from ASSURE, we ask if certain patients receiving adjuvant sunitinib for RCC are actually harmed. https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.31955 @Ron_cology
With @VPrasadMDMPH in @Annals_Oncology , we ask whether the evidence bar for adjuvant therapies must be higher than palliative therapies. https://www.annalsofoncology.org/article/S0923-7534(19)31093-2/fulltext
In this Real World Analysis, again with @Ron_cology , we show that after approval, there has been substantial increase in use of immunotherapy for urothelial cancer towards the end of life and despite poor PS. https://theoncologist.onlinelibrary.wiley.com/doi/full/10.1634/theoncologist.2019-0039
If you’re a doctor who treats patients with hepatocellular cancer, then I’d ask you to please read this paper. You don’t have to read any other paper I’ve written but please read this one. https://jnccn.org/view/journals/jnccn/17/6/article-p760.xml @JNCCN
Moving on to 2020, with our @QueensUHealth undergraduate student @sophie_effing , we studied the risks and benefits of using ramucirumab for advanced solid tumor patients. https://www.sciencedirect.com/science/article/pii/S2589537020302029
More recently, in this work with @HannaRadOnc @epipatelmd et al., we find that the real world benefits of trastuzumab for HER2+ gastric cancer are not as pronounced as seen in the pivotal ToGA trial. https://www.sciencedirect.com/science/article/abs/pii/S0936655520302958
Male cancer patients seem to have worse outcomes than females from #COVID-19. But should we really worry about that? Our editorial in @EClinicalMed with @twinbuzzing and @nazik_hammad https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30279-0/fulltext
Here is a paper with @Poudyalbishesh and @DamianoRondell1 about how viber was used urgently for establishing telehealth during lockdown in Nepal due to COVID. https://ecancer.org/en/journal/editorial/104-rapidly-established-telehealth-care-for-blood-cancer-patients-in-nepal-during-the-covid-19-pandemic-using-the-free-app-viber #jugaad
And last month, we also published the relative benefits and harms of novel #DOACs in the prophylaxis and treatment of cancer associated VTEs. https://ecancer.org/en/journal/article/1091-assessing-the-benefits-and-harms-of-direct-oral-anticoagulants-in-patients-with-cancer-for-the-prophylaxis-and-treatment-of-venous-thromboembolism-a-systematic-review-and-meta-analysis @ADesaiMD @ecancer #openaccess
